Celldex shareholders OK 3.4M share increase to equity plan; all directors re-elected

Celldex Therapeutics, Inc.

Approved 2021 Omnibus Equity Incentive Plan amendment raising share reserve by 3.4M to 12.9M shares.
All nine director nominees elected, including CEO Anthony Marucci and Chair Harry Penner Jr.
Ratification of PwC as independent auditor for FY 2026 passed with 64.7M for vs 174.7K against.
Advisory say-on-pay proposal approved: 59.2M for, 945K against, 479.7K abstain.
Plan amendment also clarifies tax withholding provisions for equity awards.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.